Dr. Wolff Group Working with Kinaxis and mSE Solutions to Bring Supply Chain Clarity to Personal Care Product Portfolio
10.9.2024 13:52:00 CEST | Business Wire | Press Release
Kinaxis® Inc. (TSX: KXS), a global leader in end-to-end supply chain orchestration, today announced that Dr. Wolff Group, a family-owned German manufacturer of cosmetic and pharmaceutical products, is working with Kinaxis, along with mSE Solutions, an expert supply chain optimization consultancy, to help drive faster and more accurate decision-making in supply chain planning and thus ensure a better balance between market and supply chain dynamics.
A growing company that exports its popular brands including Alpecin, Alcina, and Plantur among others, to more than 60 countries worldwide, Dr. Wolff faced challenges in managing its complex and diverse product portfolio that includes everything from hair care and styling products, to decorative cosmetics, dental care, and vaginal and dermatologic pharmaceuticals. In order to be able to react even more flexibly, quickly and efficiently to customer requirements, the company turned to mSE Solutions and Kinaxis to strengthen its supply chain processes.
By bringing together the strengths of their expert teams, Kinaxis and mSE Solutions will help Dr. Wolff Group in the end-to-end orchestration of the global supply chain by implementing Kinaxis' AI-powered platform.
“The diversity of our products and expansion into new markets make our supply chain particularly complex and challenging,” said Dr. Andreas Brinkhoff, Managing Director at Dr. Wolff Group. “mSE Solutions helped to identify the areas of our business that would benefit the most from supply chain orchestration technologies and by partnering with Kinaxis, we are developing a comprehensive view of our supply chain performance and risks across our entire end-to-end network. We are now prepared to respond to any disruptions.”
“Marked by hyper-competition, high volumes, and a frenetic pace, the consumer-packaged goods industry operates with a constant need for supply chain agility and efficiency,” said Martin Bilstein, regional vice president, DACH region at Kinaxis. “We’re thrilled to be part of the supply chain evolution that Dr. Wolff Group is undertaking and looking forward to supporting their success.”
To learn more about Kinaxis and its supply chain management solutions, please visit Kinaxis.com.
About Kinaxis
Kinaxis is a global leader in modern supply chain orchestration. We serve supply chains and the people who manage them in service of humanity. Our software is trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. We combine our patented concurrency technique with a human-centered approach to AI to empower businesses of all sizes to manage their end-to-end supply chain network, from multi-year strategic planning through down-to-the-second execution and last-mile delivery. For more news and information, please visit kinaxis.com or follow us on LinkedIn.
About mSE Solutions
mSE Solutions is your tech-savvy Supply Chain consultancy, dedicated to asking the right questions, providing expert guidance, and delivering top-notch services for your successful Kinaxis implementation. Our goal is to ensure that your transformation journey is quick, effective, and embraced by your users. With a global reach, our services extend to post-go-live support and system maintenance, offering comprehensive assistance wherever your business operates. For ambitious small or medium-sized enterprises – the hidden champions of their industries – mSE Solutions is the ideal, hands-on partner for Kinaxis RapidResponse implementations. Please visit mSE-solutions.com.
About Dr. Wolff-Group
Now led by the fourth generation of its founding family and with brands including Alpecin and Linola as well as Plantur, Vagisan Karex and Bioniq®, the Germany-based Dr. Wolff-Group with around 900 employees continues its global growth. Since its founding 1905, the company has maintained a strong emphasis on research and scientifically demonstrable benefits of its products for solving problems such as hair loss or skin disorders. With their own developments, the company was able to achieve a turnover of 390.6 million Euro (2023). Dr. Wolff is active in 67 countries. More information can be found at www.drwolffgroup.com/en/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240910214030/en/
Contacts
Media Relations
Jaime Cook | Kinaxis
jcook@kinaxis.com
+1 289-552-4640
Investor Relations
Rick Wadsworth | Kinaxis
rwadsworth@kinaxis.com
613-907-7613
mSE Solutions
Kerstin Olasik
kerstin.olasik@mse-solutions.com
Dr. Wolff Group
Nina Lauterbach
Nina.lauterbach@drwolffgroup.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom